Evidence map›Paper›PMID 25032860›Full record

ArticleCell death & disease2014

6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27.

A Yalcin, B F Clem, Y Imbert-Fernandez, S C Ozcan, S Peker, J O'Neal, A C Klarer, A L Clem, S Telang, J Chesney

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 203 citations in OpenAlex.

  1. Article
  2. Article
  3. The moonlighting functions of glycolytic enzymes in tumorigenesis.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  4. Article
  5. Inflammation-Insulin Resistance Crosstalk and the Central Role of Myokines.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Targeting glycolytic pathway in fibroblast-like synoviocytes for rheumatoid arthritis therapy: challenges and opportunities.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Review

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

A Yalcin1] Departments of Medicine (Hematology/Oncology) and Biochemistry and Molecular Biology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY 40202, USA [2] Department of Biochemistry, School of Veterinary Medicine, Uludag University, Bursa, Turkey.
B F ClemDepartments of Medicine (Hematology/Oncology) and Biochemistry and Molecular Biology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY 40202, USA.
Y Imbert-FernandezDepartments of Medicine (Hematology/Oncology) and Biochemistry and Molecular Biology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY 40202, USA.
S C OzcanDepartment of Biochemistry, School of Veterinary Medicine, Uludag University, Bursa, Turkey.
S PekerDepartment of Histology and Embryology, School of Veterinary Medicine, Uludag University, Bursa, Turkey.
J O'NealDepartments of Medicine (Hematology/Oncology) and Biochemistry and Molecular Biology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY 40202, USA.
A C KlarerDepartments of Medicine (Hematology/Oncology) and Biochemistry and Molecular Biology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY 40202, USA.
A L ClemDepartments of Medicine (Hematology/Oncology) and Biochemistry and Molecular Biology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY 40202, USA.
S TelangDepartments of Medicine (Hematology/Oncology) and Biochemistry and Molecular Biology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY 40202, USA.
J ChesneyDepartments of Medicine (Hematology/Oncology) and Biochemistry and Molecular Biology, University of Louisville, James Graham Brown Cancer Center, Louisville, KY 40202, USA.
University of Louisville · USBursa Uludağ Üni̇versi̇tesi̇ · TR

Funding

Activation of Cyclin-Dependent Kinases by Fructose-2,6-BisphosphateR01CA149438 · NCI · UNIVERSITY OF LOUISVILLE · PI CHESNEY, JASON A. · 2011 to 2015
$1.5M
Targeting Glucose Metabolism in CancerR01CA140991 · NCI · UNIVERSITY OF LOUISVILLE · PI TELANG, SUCHETA · 2009 to 2013
$1.1M
NCI NIH HHS NCI 1R01CA140991NCI NIH HHS NCI 1R01CA149438NCI NIH HHS R01 CA140991NCI NIH HHS R01 CA149438
6 · The paper itself

Abstract

The control of glucose metabolism and the cell cycle must be coordinated in order to guarantee sufficient ATP and anabolic substrates at distinct phases of the cell cycle. The family of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB1-4) are well established regulators of glucose metabolism via their synthesis of fructose-2,6-bisphosphate (F2,6BP), a potent allosteric activator of 6-phosphofructo-1-kinase (Pfk-1). PFKFB3 is overexpressed in human cancers, regulated by HIF-1α, Akt and PTEN, and required for the survival and growth of multiple cancer types. Although most functional studies of the role of PFKFB3 in cancer progression have invoked its well-recognized function in the regulation of glycolysis, recent observations have established that PFKFB3 also traffics to the nucleus and that its product, F2,6BP, activates cyclin-dependent kinases (Cdks). In particular, F2,6BP stimulates the Cdk-mediated phosphorylation of the Cip/Kip protein p27 (threonine 187), which in turn results in p27's ubiquitination and proteasomal degradation. As p27 is a potent suppressor of the G1/S transition and activator of apoptosis, we hypothesized that the known requirement of PFKFB3 for cell cycle progression and prevention of apoptosis may be partly due to the ability of F2,6BP to activate Cdks. In this study, we demonstrate that siRNA silencing of endogenous PFKFB3 inhibits Cdk1 activity, which in turn stabilizes p27 protein levels causing cell cycle arrest at G1/S and increased apoptosis in HeLa cells. Importantly, we demonstrate that the increase in apoptosis and suppression of the G1/S transition caused by siRNA silencing of PFKFB3 expression is reversed by co-siRNA silencing of p27. Taken together with prior publications, these observations support a model whereby PFKFB3 and F2,6BP function not only as regulators of Pfk-1 but also of Cdk1 activity, and therefore serve to couple glucose metabolism with cell proliferation and survival in transformed cells.

Indexed as

ApoptosisCell CycleCDC2 Protein KinaseCell NucleusCyclin-Dependent Kinase Inhibitor p27Down-RegulationHumansPhosphofructokinase-2PhosphorylationCDC2 Protein KinaseCyclin-Dependent Kinase Inhibitor p27PFKFB3 protein, humanPhosphofructokinase-2

Identifiers

PMID25032860
PMCPMC4123086
OpenAlexW1992606175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.